Damien Tappy
President & Managing Partner @ Endeavour Vision
Geneva, Switzerland
Damien Tappy is a Series C investor at Endeavour Vision in Geneva focused on Medical Device and Health Care. Damien Tappy - President & Managing Partner @ Endeavour Vision
- Total investments:
- 6
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Damien Tappy invests in
Stages Damien Tappy invests in
Countries Damien Tappy invests in
Investment Focus
Industry
- Medical Device 4 (67%)
- Health Care 3 (50%)
- Medical 2 (33%)
- Biotechnology 2 (33%)
- Delivery 1 (17%)
Stage
- Series C 2 (33%)
- Series A 1 (17%)
- Series D 1 (17%)
- Funding Round 1 (17%)
Country
- United States 2 (33%)
- Romania 1 (17%)
- Switzerland 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CeQur
|
CeQur SA is dedicated to developing and commercializing advanced insulin delivery systems that make it easier for people living with type 2 diabetes to comply with therapy and stay in control of their disease.CeQur is developing the CeQurâ„¢ Insulin Infuser, a simple and discrete insulin delivery tool for people who could benefit from intensiveinsulin therapy but want flexibility and freedom from multiple daily injections.CeQur was established in January 2008 as a spin out from Danfoss A/S, a large, global Danish industrial products group. The company is headquartered in Montreux, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts. | $115M / Series C / Apr 13, 2021 | |
VertiFlex
|
VertiFlex, Inc., a medical device company, provides minimally invasive and motion preserving spinal surgery technologies in the United States and internationally. The company offers superion interspinous spacer, a percutaneous titanium implant that fits between the spinous processes in the lumbar spine. Its Superion is a motion-preservinginterspinous spacer for the treatment of moderate spinal stenosis.Vertiflex Inc was founded in 2005 and is headquartered in California, USA. | $45.3M / Mar 27, 2017 | |
EndoStim
|
EndoStim is a medical device company developing therapeutics for gastrointestinal and urological neuro-muscular disorders. It is performing clinical trials to pursue FDA approval for a new treatment for sphincter-related disorders such as gastroesophageal reflux disease (GERD) and urinary urge incontinence. Its microstimulator technology provideslong-term reflux control by restoring normal esophageal function that directly targets the patient's weak or dysfunctional lower esophageal sphincter (LES) muscle between the stomach and the esophagus and enable patients to reduce or avoid typical gastrointestinal side effects of traditional anti-reflux surgery. | $25M / Series D / May 12, 2016 | |
|
CeQur
|
CeQur SA is dedicated to developing and commercializing advanced insulin delivery systems that make it easier for people living with type 2 diabetes to comply with therapy and stay in control of their disease.CeQur is developing the CeQurâ„¢ Insulin Infuser, a simple and discrete insulin delivery tool for people who could benefit from intensiveinsulin therapy but want flexibility and freedom from multiple daily injections.CeQur was established in January 2008 as a spin out from Danfoss A/S, a large, global Danish industrial products group. The company is headquartered in Montreux, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts. | $100M / Series C / Sep 01, 2015 | |
|
CeQur
|
CeQur SA is dedicated to developing and commercializing advanced insulin delivery systems that make it easier for people living with type 2 diabetes to comply with therapy and stay in control of their disease.CeQur is developing the CeQurâ„¢ Insulin Infuser, a simple and discrete insulin delivery tool for people who could benefit from intensiveinsulin therapy but want flexibility and freedom from multiple daily injections.CeQur was established in January 2008 as a spin out from Danfoss A/S, a large, global Danish industrial products group. The company is headquartered in Montreux, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts. | $29.6M / Series A / Jan 05, 2010 | |
EndoArt
|
EndoArt SA | Series C / Mar 01, 2006 |
Co-Investors
About Endeavour Vision
Endeavour Vision is a private equity firm investing in growth-stage MedTech and digital health companies. The company invests in medical innovation that provides superior clinical benefits for patients or brings significant efficiencies to health systems. Endeavour Vision team offers strategic and operational expertise and extensive internationalexperience investing in companies in Europe and North America. We have a proven track record of successful exits with recently realized investments that include Vertiflex (acquired by Boston Scientific in 2019), Medartis (IPO on SIX in Q1 2018), and Symetis (acquired by Boston Scientific in 2017). Endeavour Vision’s offices are located in Geneva, Switzerland, and Minneapolis, U.S.
Endeavour Vision Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alex Schmitz
Partner
|
|||
Bernard Vogel
Founder and Managing Partner
|
|||
|
Damien Tappy
President & Managing Partner
|
|||
Daniel van den Bergh
Senior Investment Director
|
|||
Fernando Pacheco
Investment Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Damien Tappy invest in?
Damien Tappy invests primarily in Medical Device, Health Care and Medical startups, most often at Series C and Series A stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Damien Tappy last invest?
The most recent investment recorded for Damien Tappy closed in Apr 2021. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
